Carl Baker, MD
Retina Specialist · Hilton Head Island, SCNPI 1154398253
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $28,246 of the $37,285 with a category attached, or 75.8%. Novo Nordisk accounts for 74.4% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2023 at $25,201 and has fallen 96.9% since, to $771 in 2025. Among retina specialist clinicians in SC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 162 payments — averaging $230.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$28K
- AbbVie$4K
- Novo Nordisk AS$2K
- Genentech USA, Inc.$1K
- Bausch & Lomb Americas Inc.$610
- Apellis Pharmaceuticals, Inc.$477
- plus $2K from 18 others
Across 67 payments — averaging $4888.93 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$169K
- Novo Nordisk AS$82K
- Novartis$53K
- Shire North American Group Inc$10K
- Novo Nordisk$9K
- Mylan Technologies Inc.$5K
- plus $1K from 2 others
What the payments were for
- Consulting fees$28,24676%
- Travel & lodging$3,62510%
- Food & beverage$5,39414%
- Gifts$190%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 9 | $27,754 |
| AbbVie(2 entities) | 12 | $3,799 |
| Novo Nordisk AS | 4 | $1,615 |
| Genentech USA, Inc. | 50 | $1,251 |
| Bausch & Lomb Americas Inc. | 15 | $610 |
| Apellis Pharmaceuticals, Inc. | 13 | $477 |
| Novartis | 13 | $338 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $277 |
| Regeneron Healthcare Solutions, Inc. | 11 | $267 |
| Aerie Pharmaceuticals, Inc. | 4 | $157 |
| Mallinckrodt Hospital Products Inc. | 3 | $128 |
| Shire North American Group Inc | 1 | $125 |
| Alcon | 2 | $114 |
| Coherus Oncology, Inc. | 3 | $80 |
| Biogen | 2 | $55 |
| Alimera Sciences, Inc. | 2 | $42 |
| Johnson & Johnson | 1 | $40 |
| Surgical Specialties Corporation (US), Inc. (dba Corza Medical) | 1 | $39 |
| Astellas Pharma US Inc | 2 | $35 |
| Sandoz | 1 | $26 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Astellas Pharma Global Development | 1 | $16 |
| Boston Scientific | 1 | $13 |
| Biotissue Holdings Inc. | 2 | $6 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,285 in reported general payments places this provider in the 90th percentile of 20 retina specialist providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ProlensaBromfenac Sodium | 25 | $9,760 |
| Prednisolone Acetate | 179 | $5,132 |
| Bromfenac Sodium | 17 | $3,433 |
| Timolol Maleate | 74 | $700 |
| Diclofenac Sodium | 42 | $479 |
| Ofloxacin | 28 | $345 |
| Latanoprost | 28 | $271 |
| ErythromycinErythromycin Base | 21 | $251 |
| Acetazolamide ErAcetazolamide | 14 | $234 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 14 | $199 |
| Brimonidine Tartrate | 27 | $135 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa | $277 | $9,76025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 20 retina specialist providers in South Carolina.
Other retina specialist in Hilton Head Island
- Hao TangCharleston$66K
- Adam PflugrathGreenville$13K
- Jeffrey GrossColumbia$7K
- Arman FarrRock Hill$5K
- Stephen HypesWest Columbia$5K
- James HallGreenville$4K
- Robert PrinziLittle River$4K
- Jeffrey BliceCharleston$3K
- Charles TuckerRock Hill$2K
- Nasrollah SamiyRock Hill$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.